A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Nov 2018
At a glance
- Drugs Bimekizumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms BE VIVID
- Sponsors UCB Biopharma
- 14 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated
- 04 Jan 2018 Status changed from not yet recruiting to recruiting.